For Research Use Only – Not for Human Consumption. For Research Use Only. Not for Human Consumption. Not for diagnostic, therapeutic or medical use. Statements have not been evaluated by the FDA.
CJC-1295 and Ipamorelin Together: Two Different Pituitary Signals
Tap to zoom
Key points
- A named pairing of CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist).
- No blend trials; CJC-1295 has short hormone studies and ipamorelin had a non-significant Phase 2 trial.
- Neither component is FDA-approved; both are prohibited by WADA.
What it is
This card names two constituents from different peptide classes. CJC-1295 is a GHRH analog and ipamorelin is a ghrelin-receptor agonist, so in the literature they are treated as acting through separate receptors.
How researchers study it
Research looks at each one's role in the pituitary growth-hormone axis and compares secretagogue types. The card maps the two sets of themes side by side.
What the evidence shows
No trials of the pairing exist. CJC-1295 has short studies of hormone levels, and ipamorelin had a Phase 2 trial that did not reach significance. Together that is limited evidence, and no combination benefit has been shown.
Regulatory status
The pairing is not an FDA-approved combination, neither ingredient is FDA-approved, and the World Anti-Doping Agency prohibits both.
